Mason Carrico
Stock Analyst at Stephens & Co.
(3.98)
# 601
Out of 5,106 analysts
77
Total ratings
51.47%
Success rate
12.4%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $231.95 | +1.31% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $2.12 | -5.66% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.00 | +1.33% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $11.85 | -7.17% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $36.52 | +83.46% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $134.87 | -22.15% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $15.46 | -9.44% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $20.56 | +94.55% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $108.88 | +5.62% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $42.84 | +5.04% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $102.07 | -46.12% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.86 | +23.46% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $24.13 | -29.55% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $72.50 | -28.28% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $7.21 | +177.39% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $38.63 | +6.14% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $231.95
Upside: +1.31%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $2.12
Upside: -5.66%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.00
Upside: +1.33%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $11.85
Upside: -7.17%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $36.52
Upside: +83.46%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $134.87
Upside: -22.15%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $15.46
Upside: -9.44%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $20.56
Upside: +94.55%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $108.88
Upside: +5.62%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $42.84
Upside: +5.04%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $102.07
Upside: -46.12%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.86
Upside: +23.46%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $24.13
Upside: -29.55%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $72.50
Upside: -28.28%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $7.21
Upside: +177.39%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $38.63
Upside: +6.14%